TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

Withdrawn before enrolling · Not applicable · Has a placebo group

Conditions studied: CRPS, Chronic Regional Pain Syndrome

In brief

Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient symptoms if given in early CRPS.

Key facts

Study ID

NCT02031211

Run by

Stanford University

People needed

0

Starts

2014-06-01

Expected to finish

2016-10-01

Last updated by the study team

2016-10-14

Who can join

Age: 10 and older, up to 17. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female pediatric Chronic Regional Pain Syndrome (CRPS) patients with unilateral CRPS of the lower extremity, ages 10-17 years of age.
• Patients must meet CRPS Type I diagnostic criteria and have current evidence of edema, and a temperature difference between the affected and contralateral limb ≥1.0°C.
• Duration of symptoms less than 4 months.

You may not qualify if…

• Active malignancy or history of malignancy.
• Active infection.
• History of Tuberculosis (TB) or TB exposure.
• Pregnancy.
• Concomitant disease causing immunocompromise.
• Concomitant autoimmune disease such as rheumatoid arthritis, psoriasis, ankylosing spondylitis or Crohn's Disease.
• Poorly controlled psychiatric disease including anxiety, depression or attention deficit hyperactivity disorder.
• Hepatic or renal impairment as indicated by serum transaminases and/or creatinine ≥ 150% normal value for age.
• Evidence of or history of demyelinating disease.

Where it is running

• Stanford University — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.